Sign in
Active, not recruitingNo phase

Wearable Insoles for Recurrent Diabetic Ulcer Prevention

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Status
Active, not recruiting
People taking part
17 people enrolled
Started
17 Oct 2023
Expected to end
Jan 2027
Type of study
Interventional
Treatments tested
  • Orpyx Sensory Insole System
Record updated
5 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Diagnosed Type 1 or 2 diabetes
  • Clinically diagnosed neuropathy via Neuropathy Monofilament Test (Appendix A)
  • Qualification as a "high-risk participant," meaning a recent history (<12 months) of a healed diabetic neuropathic ulceration on the weight-bearing surface of one or both feet (this includes the plantar distal toe surface)
  • Complete healing of any previous foot ulcers, as defined by complete re-epithelialization of that ulcer which is confirmed by two medical exams that occur at least two weeks apart (screening visit and baseline study visit)
  • Ability to walk independently (without use of wheelchair) for 30 steps. Use of a walker or cane is acceptable as long as the participant can walk for at least 30 steps
  • Aged >18 years
  • Ankle-Brachial Index (ABI) > 0.6 or Toe-Brachial Index (TBI) > 0.4 or palpable pulses or evidence of healing in the last 2 months. If ABI < 0.4, the patient's vascular lab studies (ABI, TBI, pulse volume recordings) will be reviewed by the study Principal Investigator and a Co-Investigator vascular surgeon
  • Subject is willing and able to maintain the required offloading (as applicable for the location of the healed ulcer)
  • Subject is willing and able to wear the Orpyx Sensory Insoles during ambulatory activity and at home during waking hours, and for a minimum of 5 hours per day
  • Amputations, if present, are compatible with the use of insoles at physician discretion (e.g. Transmetatarsal Amputation (TMA) are acceptable)

Who cannot take part

  • Current participation in another clinical investigation of a similar medical device designed to offload or prevent diabetic foot ulcer formation; or participation in such a study within 30 days prior to study enrollment, per physician discretion
  • At the start of V1, and prior to randomization, the subject no longer meets the entrance criteria (inclusion and exclusion)
  • Foot deformities or amputations that require surgical intervention as the next step in standard of care, and that the study footwear and device would not adequately address (to be adjudicated by an outside review panel)
  • Active ulcer or presence of other open chronic wound (on foot or leg), regardless of etiology (e.g., vasculitis, neoplasms, or hematological disorders)
  • Dementia
  • Psychiatric illness or social situations that would limit compliance with the study
  • Significant cardiopulmonary, severe imbalance, or other systemic disease limiting the participant's ability to walk at least 30 steps or to stand for an amount of time equal to or greater than five (5) minutes (self-reported)
  • Bunion which would predispose ulcer formation (clinician discretion)
  • Current enrollment in any other remote patient pedal monitoring (RPPM) program
  • Osteomyelitis or gangrene of the lower extremity
  • Uncorrected plantar Charcot neuroarthropathy
  • Extreme equinus
  • Above ankle amputation
  • Amputations not compatible with the insole, per physician discretion
  • Brannock-measured foot size > Men's 14 (Women's 12)
  • Physician discretion

Where in United States

  • Johns Hopkins University HospitalBaltimore, United States

About the trial

What the trial wants to find out

The primary objective of the study is to demonstrate the clinical advantages of using the Orpyx SI Sensory Insole (SI) system as an adjunct to standard of care in reducing plantar ulceration in high-risk individuals. The investigators aim to understand participant quality of life, the economic impact and cost-effectiveness of the Orpyx SI insole system, and to evaluate participant engagement and compliance.

The group in the trial

  • Orpyx Sensory Insole System InterventionTreatment being tested

    Treatment: Orpyx Sensory Insole System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 November 2026